Incyte partners with Bristol Myers Squibb on pancreatic cancer combination trial
BMY•Incyte announced a Phase 1b trial with Bristol Myers Squibb testing INCB161734 with navlimetostat in advanced or metastatic pancreatic ductal adenocarcinoma. A separate planned Phase 1b trial will test INCB161734 with Synnovation's SNV1521 in the same disease.
1. Two combination trials
Incyte announced clinical trial collaborations with Bristol Myers Squibb and Synnovation to evaluate INCB161734 combinations in pancreatic ductal adenocarcinoma. A Phase 1b trial will test the drug with Bristol Myers Squibb's MTA-cooperative PRMT5 inhibitor navlimetostat, while a separate planned Phase 1b trial will evaluate it with Synnovation's PARP1 inhibitor SNV1521; both trials are in advanced or metastatic disease.
